( OTC-BB:TPIV )

News from tapimmune inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 21, 2016, 08:30 ET TapImmune Doses First Patient in Its Phase 2 Triple Negative Breast Cancer Trial for Cancer Vaccine TPIV 200

TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based...


Jun 07, 2016, 08:00 ET TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine

TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company is pleased to announce that the Company has exercised its option...


Jun 06, 2016, 09:00 ET TapImmune to Present at the LD Micro Invitational in Los Angeles on June 7, 2016

TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based...


May 27, 2016, 11:43 ET TapImmune to Present at SeeThruEquity and Marcum Conferences in New York City

TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based...


Apr 28, 2016, 08:30 ET TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016

TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based...


Apr 21, 2016, 09:15 ET TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute

- Study to commence Q2 2016 at Sloan Kettering Institute  - Cancer vaccine and checkpoint inhibitor combination to be evaluated in...


Apr 07, 2016, 08:30 ET TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine

  - Doses for use at Mayo Clinic and other clinical sites  - Stable, easily reconstituted product contains five...


Mar 14, 2016, 08:58 ET TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based...


Feb 18, 2016, 09:00 ET TapImmune Receives Notice of Allowance on U.S. Patent Claims for PolyStart - Next-Generation T-Cell Vaccine

  - Proprietary DNA Expression Vector Technology Developed at TapImmune's Laboratories - PolyStart to Move into Clinical...


Feb 10, 2016, 08:30 ET TapImmune Sponsors 26.2 With DONNA Marathon for Breast Cancer Research and Care

Events & Marathon to take place in Jacksonville, Florida on February 12-14, 2016 TapImmune, Inc. (TPIV), a clinical-stage onco-immunology...


Feb 08, 2016, 08:30 ET TapImmune to Present at Source Capital's 2016 Disruptive Growth & Healthcare Conference on February 10, 2016

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based...


Feb 03, 2016, 08:30 ET TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer

- Expedites TapImmune's clinical development program for ovarian cancer  - Follows recent Orphan Drug Designation for TPIV 200 in...


Jan 27, 2016, 08:30 ET TapImmune Appoints Frederick G. Wasserman to its Board of Directors

TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based...


Jan 07, 2016, 09:15 ET TapImmune to Present at Biotech Showcase 2016 in San Francisco on January 11, 2016

TapImmune, Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based...


Dec 10, 2015, 08:30 ET TapImmune Presents New Data at San Antonio Breast Cancer Symposium Showing Robust Generation of T-Cell Immunity

- Vaccination with TPIV 100 boosts T-cell immunity to HER2 in HER2+ Breast Cancer Patients   - Provides catalyst to start Phase...


Dec 09, 2015, 15:51 ET U.S. Food & Drug Administration Grants Orphan Drug Designation to TapImmune's TPIV 200 in the Treatment of Ovarian Cancer

TapImmune, Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based...


Dec 07, 2015, 08:30 ET TapImmune to Present New Data at San Antonio Breast Cancer Symposium on December 10, 2015

TapImmune, Inc. (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based...


Nov 30, 2015, 08:30 ET TapImmune to Present at LD Micro Main Event on December 1, 2015

TapImmune, Inc. (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based...


Nov 05, 2015, 08:30 ET Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters to Jacksonville Florida

TapImmune Inc., (OTCMKTS: TPIV) a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based...


Oct 13, 2015, 08:00 ET TapImmune to Present at Dawson James Small Cap Growth Conference in Florida on October 15, 2015

TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based...


Oct 07, 2015, 08:30 ET TapImmune to Present at Aegis Capital 2015 Growth Conference in Las Vegas on October 9, 2015

TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based...


Sep 15, 2015, 08:30 ET TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer

TapImmune, Inc. (OTCMKTS: TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S. Department of Defense. This...


Sep 10, 2015, 10:11 ET TapImmune To Provide Update On and Confirmation Of Phase II Clinic Trial Initiation

 TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company will hold a conference call on Wednesday, September 16 at 11:00...


Sep 08, 2015, 08:00 ET TapImmune Inc to Present at the SeeThruEquities Fall

 TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and...


Sep 02, 2015, 08:00 ET TapImmune Inc. to Present at 17th Annual Rodman & Renshaw Healthcare Conference

 TapImmune, Inc. ( OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based...